- Home
- The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
Taking the recent ACC heart failure guideline updates as its core theme, this symposium will provide a succinct overview of the changes with one of the guideline’s primary authors. We will then consider how guidelines have evolved to accommodate the growing number of foundational treatments for heart failure and how we are moving towards personalised care. We also take a look at HFpEF, and assess how our treatment options have changed and what else can be expected for this population.
This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.
Support Statement
This programme is supported by an unrestricted educational grant from AstraZeneca. The scientific programme has not been influenced in any way by the sponsors.
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
- Compare updates from the ACC with the 2021 ESC HF guidelines
- Recall guideline recommendations for the initiation of foundational therapy for heart failure
- Adopt foundational GMDT early in the disease course
- Postulate how ejection fraction will be used in future trials and in future guidelines
- Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Presentation & Discussion | The ACC Heart Failure Guidelines 2022: What Did We Learn? | 15 mins | Biykem Bozkurt (Texas, US ) |
| Presentation & Discussion | The Future of Guidelines: Towards Personalised Care | 15 mins | Mikhail Kosiborod (Kansas, US ) |
| Presentation & Discussion | HFpEF: The Final Chapter in the Heart Failure Story? | 15 mins | Andrew JS Coats (Warwick, UK ) |
The ACC Heart Failure Guidelines 2022: What Did We Learn?
Duration: 15 mins
Speakers: Biykem Bozkurt (Texas, US )
The Future of Guidelines: Towards Personalised Care
Duration: 15 mins
Speakers: Mikhail Kosiborod (Kansas, US )
HFpEF: The Final Chapter in the Heart Failure Story?
Duration: 15 mins
Speakers: Andrew JS Coats (Warwick, UK )
Related Courses
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- Not accredited
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points